China Pharma Holdings Cash Flow from Operating Activities 2010-2023 | CPHI

China Pharma Holdings cash flow from operating activities from 2010 to 2023. Cash flow from operating activities can be defined as a company's cash flows from operations.
China Pharma Holdings Annual Cash Flow Ops
(Millions of US $)
2023 $-1
2022 $-0
2021 $-0
2020 $-0
2019 $1
2018 $2
2017 $1
2016 $3
2015 $3
2014 $6
2013 $9
2012 $4
2011 $5
2010 $8
2009 $11
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.007B
CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $18.218B 6.35
Dr Reddy's Laboratories (RDY) India $11.543B 17.16
Aspen Pharmacare (APNHY) South Africa $5.511B 0.00
BridgeBio Pharma (BBIO) United States $5.445B 0.00
Bausch Health Cos (BHC) Canada $2.524B 1.92
Amphastar Pharmaceuticals (AMPH) United States $2.030B 12.41
Supernus Pharmaceuticals (SUPN) United States $1.592B 0.00
Taysha Gene Therapies (TSHA) United States $0.438B 0.00
Generation Bio (GBIO) United States $0.199B 0.00
Personalis (PSNL) United States $0.082B 0.00
Assembly Biosciences (ASMB) United States $0.074B 0.00
Acasti Pharma (ACST) Canada $0.026B 0.00
Sol-Gel Technologies (SLGL) Israel $0.019B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00